Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,exchangeDataDelayedBy,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,fax,industry,address2
t0,IVBXF,8747145000,210016992,521749500,,-127023500,,-195113500,572137500,1203774000,109887000,109887000,,-17868500,,,,68090000,1429806500,1319919500,226032500,-236910500,,-195113500,-195113500,32625000,18541251000,3055226000,8779770000,279812000,11834996000,97000,64692000,-9981989000,633964000,220411000,411545000,7763833000,1485851000,255000000,220411000,1911203000,9466681000,12942000,575201000,925178000,705658000,120620000,-1775171500,-63548500,-2118314500,116296000,1362948000,171639500,1268936500,-846189500,-308782500,217959500,14599500,-115696500,-101444000,-47676500,-22284500,439503000,-211138000,7980830000,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,INNOVENT BIOLOGICS INC,us_market,2,Other OTC,"Innovent Biologics, Inc.",CNY,6498,97,7.1,2.0882351,3.4 - 13.5,-3.0,-0.22222222,3.4,13.5,0,10.57606,-0.076060295,-0.007191742,7.9416094,2.5583906,0.32215014,2205178368,15,America/New_York,EDT,-14400000,False,False,0.0,10.5 - 10.5,10.5,finmb_141109936,10.5,1629475515,0.0,10.5,10.5,10.5,50,0.0,,,13.5,3.4,10.58,7.94,6.5k,97,210.02M,,1.19B,7.80%,41.84%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",-25.98%,-14.50%,-3.65%,-14.75%,3.84B,2.83,307.30%,3.07B,-489.2M,-998.42M,,,8.12B,5.79,1.21B,13.74,6.37,,-307.69M,-806.08M,Value,215123,,3279,"Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib in China; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.",Suzhou,86 512 6956 6088,China,http://www.innoventbio.com,86400,168 Dongping Street,86 512 6956 6088,,Suzhou Industrial Park
t-1,IVBXF,8747145000,210016992,521749500,,-127023500,,-195113500,572137500,1203774000,109887000,109887000,,-17868500,,,,68090000,1429806500,1319919500,226032500,-236910500,,-195113500,-195113500,32625000,18541251000,3055226000,8779770000,279812000,11834996000,97000,64692000,-9981989000,633964000,220411000,411545000,7763833000,1485851000,255000000,220411000,1911203000,9466681000,12942000,575201000,925178000,705658000,120620000,-1775171500,-63548500,-2118314500,116296000,1362948000,171639500,1268936500,-846189500,-308782500,217959500,14599500,-115696500,-101444000,-47676500,-22284500,439503000,-211138000,7980830000,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,INNOVENT BIOLOGICS INC,us_market,2,Other OTC,"Innovent Biologics, Inc.",CNY,6498,97,7.1,2.0882351,3.4 - 13.5,-3.0,-0.22222222,3.4,13.5,0,10.57606,-0.076060295,-0.007191742,7.9416094,2.5583906,0.32215014,2205178368,15,America/New_York,EDT,-14400000,False,False,0.0,10.5 - 10.5,10.5,finmb_141109936,10.5,1629475515,0.0,10.5,10.5,10.5,50,0.0,,,13.5,3.4,10.58,7.94,6.5k,97,210.02M,,1.19B,7.80%,41.84%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",-25.98%,-14.50%,-3.65%,-14.75%,3.84B,2.83,307.30%,3.07B,-489.2M,-998.42M,,,8.12B,5.79,1.21B,13.74,6.37,,-307.69M,-806.08M,Value,215123,,3279,"Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib in China; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.",Suzhou,86 512 6956 6088,China,http://www.innoventbio.com,86400,168 Dongping Street,86 512 6956 6088,,Suzhou Industrial Park
t-2,IVBXF,6369358000,210016992,403977000,,-302333000,,-304097000,316729000,332226500,-388479500,-388479500,,-16306500,,,,1764000,492103000,880582500,159876500,86146500,,-304097000,-304097000,35207000,15989064000,2549627000,6404565000,173987000,8954192000,93000,69968000,-9591762000,655339000,7170000,279835000,4633286000,1084885000,146000000,7170000,1474694000,7162472000,1984000,430967000,793000000,467136000,196065000,-469807000,109282000,-473979500,52899000,1093112500,-116018000,1062245000,271375500,24046000,-371803500,28214000,29185500,-54269500,-64993000,-22031500,30078000,-33373000,6077587000,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,INNOVENT BIOLOGICS INC,us_market,2,Other OTC,"Innovent Biologics, Inc.",CNY,6498,97,7.1,2.0882351,3.4 - 13.5,-3.0,-0.22222222,3.4,13.5,0,10.57606,-0.076060295,-0.007191742,7.9416094,2.5583906,0.32215014,2205178368,15,America/New_York,EDT,-14400000,False,False,0.0,10.5 - 10.5,10.5,finmb_141109936,10.5,1629475515,0.0,10.5,10.5,10.5,50,0.0,,,13.5,3.4,10.58,7.94,6.5k,97,210.02M,,1.19B,7.80%,41.84%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",-25.98%,-14.50%,-3.65%,-14.75%,3.84B,2.83,307.30%,3.07B,-489.2M,-998.42M,,,8.12B,5.79,1.21B,13.74,6.37,,-307.69M,-806.08M,Value,215123,,3279,"Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib in China; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.",Suzhou,86 512 6956 6088,China,http://www.innoventbio.com,86400,168 Dongping Street,86 512 6956 6088,,Suzhou Industrial Park
t-3,IVBXF,6369358000,210016992,403977000,,-302333000,,-304097000,316729000,332226500,-388479500,-388479500,,-16306500,,,,1764000,492103000,880582500,159876500,86146500,,-304097000,-304097000,35207000,15989064000,2549627000,6404565000,173987000,8954192000,93000,69968000,-9591762000,655339000,7170000,279835000,4633286000,1084885000,146000000,7170000,1474694000,7162472000,1984000,430967000,793000000,467136000,196065000,-469807000,109282000,-473979500,52899000,1093112500,-116018000,1062245000,271375500,24046000,-371803500,28214000,29185500,-54269500,-64993000,-22031500,30078000,-33373000,6077587000,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,INNOVENT BIOLOGICS INC,us_market,2,Other OTC,"Innovent Biologics, Inc.",CNY,6498,97,7.1,2.0882351,3.4 - 13.5,-3.0,-0.22222222,3.4,13.5,0,10.57606,-0.076060295,-0.007191742,7.9416094,2.5583906,0.32215014,2205178368,15,America/New_York,EDT,-14400000,False,False,0.0,10.5 - 10.5,10.5,finmb_141109936,10.5,1629475515,0.0,10.5,10.5,10.5,50,0.0,,,13.5,3.4,10.58,7.94,6.5k,97,210.02M,,1.19B,7.80%,41.84%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",-25.98%,-14.50%,-3.65%,-14.75%,3.84B,2.83,307.30%,3.07B,-489.2M,-998.42M,,,8.12B,5.79,1.21B,13.74,6.37,,-307.69M,-806.08M,Value,215123,,3279,"Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib in China; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.",Suzhou,86 512 6956 6088,China,http://www.innoventbio.com,86400,168 Dongping Street,86 512 6956 6088,,Suzhou Industrial Park
